Investment analysts at StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a note issued to investors on Friday. The firm set a “sell” rating on the biopharmaceutical company’s stock.
Akari Therapeutics Stock Up 2.7 %
AKTX opened at $2.27 on Friday. Akari Therapeutics has a 52 week low of $1.08 and a 52 week high of $4.40. The business’s fifty day simple moving average is $3.14 and its 200 day simple moving average is $2.72.
About Akari Therapeutics
Further Reading
- Five stocks we like better than Akari Therapeutics
- Investing In Preferred Stock vs. Common Stock
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- High Flyers: 3 Natural Gas Stocks for March 2022
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- Consumer Staples Stocks, Explained
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.